scholarly journals Venous and Lung Thromboembolism in the Context of Lung Cancer: Clinical Manifestations, Risk Factors and Prognosis

2019 ◽  
Vol 32 (10) ◽  
pp. 647 ◽  
Author(s):  
Rosana Maia ◽  
Inês Neves ◽  
António Morais ◽  
Henrique Queiroga
Keyword(s):  
Lung Cancer ◽  
Venous Thromboembolism ◽  
Cancer Diagnosis ◽  
Negative Impact ◽  
Clinical Manifestations ◽  
Research Subjects ◽  
Lung Cancer Diagnosis ◽  
The Impact ◽  
The Relationship

Introduction: The relationship between cancer and thromboembolic events has been known for a long time. Lung and venous thromboembolism are frequent complications of lung cancer and its treatment, being a great cause of morbidity and mortality. We pretend to establish the relationship between lung and venous thromboembolism and lung cancer, describe patient characteristics and analyze the impact in the survival and prognosis.Material and Methods: It was a retrospective study. All research subjects were selected from lung cancer patients with a newly diagnosed lung and venous thromboembolism event admitted to Hospital S. João, between January 2008 and December 2013 and were followed until December 2014. Statistical analysis was performed with SPSS.Results: From the search, we obtained 113 patients. The majority was male, smokers or ex-smokers, and adenocarcinoma was the most frequent histologic type, being diagnosed mostly in advanced stages. We noticed that the median time between lung cancer diagnosis and lung venous thromboembolism was 2.9 months. In 24 patients (21.4%), the lung cancer diagnosis occurred after the lung and venous thromboembolism event and in 86 patients (76.8%), it occurred before the event. After a median follow up of 1.4 months, 107 (94.7%) patients died, 1 (0.9%) was lost to follow-up and 5 (4.4%) were still alive. The median survival rate was 1.5 months.Discussion: The diagnosis of lung and venous thromboembolism in patients with lung cancer is associated with bad prognosis. It occurs most frequently in patients with advanced disease, in the first months after lung cancer diagnosis and after beginning chemotherapy.Conclusion: Disease progression is an independent predictor with negative impact in overall survival.

RELEVANCE OF ANTI-TUMOR ANTIBODIES AS NOVEL INDICATORS IN LUNG CANCER DIAGNOSIS, TREATMENT AND FOLLOW-UP

2012 ◽  
Vol 6 (1) ◽  
pp. 20-26
Author(s):  
Ali Osmay Gure ◽  
Burcak Vural ◽  
Ugur Ozbek ◽  
Nalan Demir Firat ◽  
Ismail Savas
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Lung Cancer Diagnosis

scholarly journals Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Ji Young Park ◽  
Ye Jin Lee ◽  
Taehee Kim ◽  
Chang Youl Lee ◽  
Hwan Il Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Rapid Progression ◽  
Lung Cancers ◽  
The Past ◽  
Lung Cancer Diagnosis ◽  
Number Of Patients ◽  
Wide Range ◽  
Collateral Effects ◽  
The Impact

Abstract Background The COVID-19 pandemic is predicted to significantly affect patients with lung cancer, owing to its rapid progression and high mortality. Studies on lung cancer diagnosis and treatment during an epidemic are lacking. We analyzed the impact of COVID-19 on lung cancer diagnosis in Korea, where lung cancer incidence continues to rise. Methods The number of newly diagnosed lung cancer cases in three university-affiliated hospitals during the pandemic and their clinical features were compared with lung cancer cases diagnosed during the same period in the past 3 years. The effectiveness of measures taken by the study hospitals to prevent nosocomial transmission was reviewed. Results A total of 612 patients were diagnosed with lung cancer from February through June, 2017–2020. During the pandemic, the number of patients who sought consultation at the division of pulmonology of study hospitals dropped by 16% from the previous year. Responding to the pandemic, the involved hospitals created physically isolated triage areas for patients with acute respiratory infection symptoms. Wide-range screening and preventive measures were implemented, thus minimizing the delay in lung cancer diagnosis. No patient acquired COVID-19 due to hospital exposure. The proportion of patients with stage III–IV non-small-cell lung cancer (NSCLC) significantly increased (2020: 74.7% vs. 2017: 57.9%, 2018: 66.7%, 2019: 62.7%, p = 0.011). The number of lung cancers diagnosed during this period and the previous year remained the same. Conclusions The proportion of patients with advanced NSCLC increased during the COVID-19 pandemic.

Not Following the Rules in Guideline Care for Lung Cancer Diagnosis and Staging Has Negative Impact

2020 ◽  
Vol 110 (5) ◽  
pp. 1730-1738
Author(s):  
Candice L. Wilshire ◽  
Joshua R. Rayburn ◽  
Shu-Ching Chang ◽  
Christopher R. Gilbert ◽  
Brian E. Louie ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Negative Impact ◽  
Lung Cancer Diagnosis ◽  
Guideline Care

scholarly journals Characteristics and Predictors of Missed Opportunities in Lung Cancer Diagnosis: An Electronic Health Record–Based Study

2010 ◽  
Vol 28 (20) ◽  
pp. 3307-3315 ◽  
Author(s):  
Hardeep Singh ◽  
Kamal Hirani ◽  
Himabindu Kadiyala ◽  
Olga Rudomiotov ◽  
Traber Davis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Type I ◽  
Type Ii ◽  
Missed Opportunities ◽  
X Ray ◽  
Lung Cancer Diagnosis ◽  
Abnormal Chest ◽  
Chest X Ray

Purpose Understanding delays in cancer diagnosis requires detailed information about timely recognition and follow-up of signs and symptoms. This information has been difficult to ascertain from paper-based records. We used an integrated electronic health record (EHR) to identify characteristics and predictors of missed opportunities for earlier diagnosis of lung cancer. Methods Using a retrospective cohort design, we evaluated 587 patients of primary lung cancer at two tertiary care facilities. Two physicians independently reviewed each case, and disagreements were resolved by consensus. Type I missed opportunities were defined as failure to recognize predefined clinical clues (ie, no documented follow-up) within 7 days. Type II missed opportunities were defined as failure to complete a requested follow-up action within 30 days. Results Reviewers identified missed opportunities in 222 (37.8%) of 587 patients. Median time to diagnosis in cases with and without missed opportunities was 132 days and 19 days, respectively (P < .001). Abnormal chest x-ray was the clue most frequently associated with type I missed opportunities (62%). Follow-up on abnormal chest x-ray (odds ratio [OR], 2.07; 95% CI, 1.04 to 4.13) and completion of first needle biopsy (OR, 3.02; 95% CI, 1.76 to 5.18) were associated with type II missed opportunities. Patient adherence contributed to 44% of patients with missed opportunities. Conclusion Preventable delays in lung cancer diagnosis arose mostly from failure to recognize documented abnormal imaging results and failure to complete key diagnostic procedures in a timely manner. Potential solutions include EHR-based strategies to improve recognition of abnormal imaging and track patients with suspected cancers.

scholarly journals The impact of the COVID-19 pandemic on lung cancer diagnosis and stage at Plymouth NHS Trust

Lung Cancer ◽  
2021 ◽  
Vol 156 ◽  
pp. S17
Author(s):  
Helen McDill ◽  
Maged Hassan ◽  
Lindsey Taylor ◽  
John Corcoran ◽  
Cyrus Daneshvar
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Lung Cancer Diagnosis ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document